1. Home
  2. LXRX vs EMD Comparison

LXRX vs EMD Comparison

Compare LXRX & EMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LXRX
  • EMD
  • Stock Information
  • Founded
  • LXRX 1995
  • EMD 2003
  • Country
  • LXRX United States
  • EMD United States
  • Employees
  • LXRX N/A
  • EMD N/A
  • Industry
  • LXRX Biotechnology: Pharmaceutical Preparations
  • EMD Finance/Investors Services
  • Sector
  • LXRX Health Care
  • EMD Finance
  • Exchange
  • LXRX Nasdaq
  • EMD Nasdaq
  • Market Cap
  • LXRX 650.7M
  • EMD 576.8M
  • IPO Year
  • LXRX 2000
  • EMD N/A
  • Fundamental
  • Price
  • LXRX $0.98
  • EMD $9.62
  • Analyst Decision
  • LXRX Buy
  • EMD
  • Analyst Count
  • LXRX 2
  • EMD 0
  • Target Price
  • LXRX $6.00
  • EMD N/A
  • AVG Volume (30 Days)
  • LXRX 4.3M
  • EMD 248.5K
  • Earning Date
  • LXRX 11-12-2024
  • EMD 01-01-0001
  • Dividend Yield
  • LXRX N/A
  • EMD 10.25%
  • EPS Growth
  • LXRX N/A
  • EMD N/A
  • EPS
  • LXRX N/A
  • EMD N/A
  • Revenue
  • LXRX $5,229,000.00
  • EMD N/A
  • Revenue This Year
  • LXRX $1,212.46
  • EMD N/A
  • Revenue Next Year
  • LXRX $219.10
  • EMD N/A
  • P/E Ratio
  • LXRX N/A
  • EMD N/A
  • Revenue Growth
  • LXRX 886.60
  • EMD N/A
  • 52 Week Low
  • LXRX $0.97
  • EMD $7.85
  • 52 Week High
  • LXRX $3.73
  • EMD $9.55
  • Technical
  • Relative Strength Index (RSI)
  • LXRX 25.78
  • EMD 35.80
  • Support Level
  • LXRX $1.01
  • EMD $9.61
  • Resistance Level
  • LXRX $1.35
  • EMD $9.85
  • Average True Range (ATR)
  • LXRX 0.12
  • EMD 0.12
  • MACD
  • LXRX -0.06
  • EMD -0.01
  • Stochastic Oscillator
  • LXRX 0.43
  • EMD 4.81

About LXRX Lexicon Pharmaceuticals Inc.

Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain; and sotagliflozin, an orally-delivered small molecule drug candidate, as a treatment for heart failure and type 1 diabetes.

About EMD Western Asset Emerging Markets Debt Fund Inc

Western Asset Emg Markets Debt Fund Inc is a non-diversified closed-end management investment company. Its primary investment objective is to seek high current income and the secondary objective is to seek capital appreciation.

Share on Social Networks: